Audited Supplier
Why do we test HPV?
Cervical cancer is a leading cause of mortality among women. In 2020, an estimated 604 000 women were diagnosed with cervical cancer worldwide and about 342 000 women died from the disease. In the new WHO guideline for screening and treatment of cervical pre-cancer les -ions for cervical cancer prevention, WHO suggests among the general population of women at the age of 30 years screening HPV every 5 to 10 years.WHO suggests using an HPV DNA primary screening test either with triage or without triage to prevent cervical cancer among the general population of wome
ULTRASSAY HPV Detection Series Products
UBP-C00650H (Primary Screening): This kit is intended to qualitatively detect the DNA of 28 types of HPV and at the same time identify the HPVs as high-risk group, medium-risk group, or low-risk group.
Recommended plan: It is suitable for early screening of HPV-related diseases (including cervical cancer) to determine the risk classification of cervical lesions.
UBP-C00432H (Genotyping Identification): This kit is intended to qualitatively detect the DNA of 28 types of HPV and identify the genotypes.
Recommended plan: It has a complete range of genotypes, covering all common medium risk and high risks HPV types detection.
UBP-C00350H: This kit is intended to qualitatively detect 2 high risk types 16, 18 and screening other 12 genotypes in 1 reaction.
Recommended plan: Efficient and direct HPV detection solution for cervical cancel screening.
[Advantage]
- Accurate Results: By using multiplex fluorescence PCR technology that reacts in fully enclosed system.
- Specificity: No cross-reaction with other fusion genes.
- Sensitivity: Limit of detection to 100 copies/reaction.
- Reliable: Internal reference and blank control, positive control of the whole process quality control.
